IDEAYA Biosciences Inc. (NASDAQ: IDYA) and Servier reported results from their phase 2/3 OptimUM-02 trial of darovasertib in combination with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE